SCHEDULE 13D/A: Ernexa Therapeutics Investor Boosts Stake to 32.8% Amidst $7.25 Million Private Placement

Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 32.8% through participation in a two-tranche private placement totaling approximately $7.25 million.

Summary

• Charles Cherington, the reporting person, has increased his beneficial ownership in Ernexa Therapeutics Inc. to 20,432,634 shares, representing 32.8% of the company's Common Stock.
• This ownership includes 20,401,602 shares of Common Stock and 31,032 shares issuable upon conversion of Series A convertible preferred stock.
• The calculation of the 32.8% ownership is based on an aggregate of 62,209,977 shares of Common Stock outstanding, which includes shares reported in the company's 10-K, shares sold in the First Closing of the Private Placement, and convertible preferred shares.
• Ernexa Therapeutics Inc. entered into a Securities Purchase Agreement on April 2, 2025, for a private placement to issue approximately 58,262,918 shares (or pre-funded warrants) at $0.1046 per share, aiming to raise approximately $7,250,000.
• The private placement is structured in two closings to comply with Nasdaq Listing Rules 5635(b) and 5635(d).
• The First Closing occurred on April 2, 2025, where 9,934,016 shares of Common Stock and pre-funded warrants for 509,736 shares were sold.
• In the First Closing, Charles Cherington acquired 3,768,397 shares of Ernexa's Common Stock.
• The Second Closing, which includes the sale of an additional 48,328,902 shares and pre-funded warrants for 10,539,000 shares, is conditioned upon stockholder approval of the Private Placement.
• If the Second Closing proceeds, Charles Cherington is expected to receive an additional 21,241,163 shares of Common Stock.
• The Issuer has committed to hold a stockholder meeting for approval by June 30, 2025, or July 30, 2025, if the SEC reviews the preliminary proxy statement.
• Purchasers, including Charles Cherington, have agreed to vote all their existing voting capital stock (excluding shares from the First Closing) in favor of the Private Placement.
• The Issuer will file registration statements for the resale of shares from the First Closing within 15 days and from the Second Closing within 10 days after that closing.

Sentiment

Score: 6

Explanation: The document outlines a significant capital raise, which is generally positive for a company's financial stability and future operations. However, the substantial dilution for existing shareholders and the contingency of the second tranche on stockholder approval introduce some neutral or potentially negative aspects. The overall sentiment leans slightly positive due to the successful securing of funding.

Positives

• The company is securing significant capital through a private placement, totaling approximately $7,250,000, which can support its operations and strategic initiatives.
• A major existing shareholder, Charles Cherington, is demonstrating continued confidence by substantially increasing his stake in the company through participation in the private placement.
• The structured two-closing approach ensures compliance with Nasdaq listing rules, facilitating the capital raise process.

Negatives

• The private placement involves the issuance of a large number of shares (approximately 58.26 million), which will result in significant dilution for existing shareholders not participating in the offering.
• The Second Closing, which accounts for the majority of the capital raise, is contingent upon stockholder approval, introducing a degree of uncertainty.
• The purchase price of $0.1046 per share may be significantly lower than the market price, indicating a discounted offering to attract investors and potentially impacting existing shareholder value.

Risks

• The Second Closing of the Private Placement is conditioned on stockholder approval; if not obtained, the company will not receive the full anticipated capital.
• Delays in SEC review of the preliminary proxy statement could push back the stockholder meeting and subsequently the Second Closing.
• Delays in SEC review of the registration statements for resale of shares could impact the liquidity for investors participating in the private placement.
• The significant increase in outstanding shares due to the private placement could lead to substantial dilution for current shareholders, potentially impacting per-share metrics and stock price.

Future Outlook

The company anticipates completing the Second Closing of its private placement, contingent on stockholder approval, by late June or July 2025. Following each closing, the company plans to file registration statements for the resale of the newly issued shares, aiming for effectiveness within 30-60 days depending on SEC review.

Management Comments

• The Reporting Person agrees to appoint the Chief Executive Officer of the Issuer to act as the proxy for the Reporting Person's shares that are permitted to vote at any stockholder meeting, should the Reporting Person fail to vote their shares in favor of the Private Placement as per the Purchase Agreement.

Industry Context

This filing details a significant capital raise for Ernexa Therapeutics Inc., a common occurrence for companies, particularly in the biotechnology or early-stage sectors, that require substantial funding for research, development, or operational expenses. Private placements are a frequent method for such companies to secure capital from accredited investors, often involving existing large shareholders, to bypass the more extensive and time-consuming process of a public offering. The need for stockholder approval for a large issuance is typical for Nasdaq-listed companies to prevent excessive dilution without shareholder consent.

Comparison to Industry Standards

• The private placement structure, including a two-tranche closing and the requirement for stockholder approval for the larger tranche, is a standard approach for Nasdaq-listed companies to comply with listing rules (e.g., Nasdaq Listing Rules 5635(b) and 5635(d)) when issuing shares that exceed certain thresholds (e.g., 20% of outstanding shares or voting power).
• The pricing of $0.1046 per share, while specific to Ernexa, is typical for private placements where shares are offered at a discount to attract investors, especially for companies seeking significant capital infusions.
• The commitment to file resale registration statements within specific timeframes (15 days for First Closing, 10 days for Second Closing) and target effectiveness dates (45-60 days) is standard practice to ensure liquidity for the private placement investors.

Corporate Governance

Related Party Transactions

• Charles Cherington, a significant beneficial owner (32.8% post-First Closing), is participating as an accredited investor in the private placement, acquiring 3,768,397 shares in the First Closing and expecting 21,241,163 shares in the Second Closing.

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the large number of shares issued in the private placement, but the capital raise could improve the company's financial stability and prospects.
• Company: Will receive approximately $7.25 million in capital, which can be used for operations, research, and development, strengthening its financial position.
• Investors (participating in private placement): Will acquire shares at a discounted price of $0.1046 per share and will have their shares registered for resale, providing liquidity.

Next Steps

• The Issuer will hold a meeting of its stockholders to obtain approval for the Private Placement, expected by June 30, 2025, or July 30, 2025, if the SEC reviews the proxy statement.
• Upon stockholder approval, the Second Closing of the Private Placement will take place, where an additional 48,328,902 shares and pre-funded warrants will be issued.
• The Issuer will file a registration statement for the resale of shares issued in the First Closing within 15 days of April 2, 2025.
• The Issuer will file an additional registration statement for the resale of shares issued in the Second Closing within 10 days after that closing.

Key Dates

Keywords

Ernexa Therapeutics, Private Placement, Schedule 13D, Beneficial Ownership, Capital Raise, Common Stock, Shareholder Approval, Nasdaq Listing Rules, Dilution, Convertible Preferred Stock